ReviewPharmacoEconomics2018

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Iñigo Bermejo et al.PubMed ↗Publisher ↗

No numbers read from the abstract.